News

For the 2009 second quarter, Schering-Plough has reported GAAP net income of $633m or 38 cents per common share, compared to $424m or 26 cents per common share

Lexicon has received orphan drug designation from the European Medicines Agency (EMEA) for LX1032. It is intended for managing gastrointestinal symptoms associated with carcinoid syndrome.   LX1032 is

Debiopharm has received marketing authorisation for Moapar 11.25mg, from Swissmedic. Moapar 11.25mg is intended for a reversible reduction of serum testosterone to the level of castration in adult

Incyte has reached an agreement with the FDA regarding a Special Protocol Assessment. This SPA is on the design of a pivotal phase III trial for JAK1/JAK2 Inhibitor

Compugen’s CGEN-25017, a novel peptide antagonist of the Angiopoietin/Tie-2 pathway, has shown positive therapeutic effects in an animal model of retinopathy. CGEN-25017 had previously demonstrated significant inhibitory activity

Premier Insurance Management Services (PIMS) has announced a new professional medical liability insurance program. The program offers risk management and hospital medical malpractice protection to not-for-profit hospital members

Zynx Health and eClinicalWorks have announced a partnership to provide Zynx AmbulatoryCare order sets to eClinicalWorks clients. The evidence-based content is expected to provide a solution to help

Asuragen has entered into an agreement with Biogen Idec to identify a potential companion diagnostic test, that may be used to select patients likely to respond to a

Vertex Pharmaceuticals, a biotechnology company, has completed its acquisition of ViroChem Pharma, a privately-held company with two investigational HCV polymerase inhibitors in clinical development. ViroChem shareholders received $100